remdesivir / Generic mfg. - LARVOL DELTA

Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential. (PubMed, PLoS One) - "In order to increase the protective strength of remdesivir we took couple of approaches, one, to make an alternative but better derivative of remdesivir as remdesivir bis-propionate, and the other is to use our platform- designed biopolymer (NV387) to protect remdesivir compound from degradation in presence of plasma. (3) The antiviral activity is also increased against NL-63 infection to rat model, compared to naked and/or encapsulated remdesivir. (4) The antiviral efficacy of the remdesivir pro-drug, therefore, can be mathematically drawn as follows: remdesivir-bP-encapsulated > remdesivir-encapsulated > remdesivir-bP > remdesivir."

Clinical • Journal • PK/PD data • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Profile of clinical trials with drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Spain. (PubMed, Farm Hosp) - "We conclude that there is a need to improve transparency, record all results- including negative ones- and review key aspects of design and funding, as recommendations for future research, including in health emergencies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Evaluation of artificial intelligence identified ipratropium bromide for the treatment of coronavirus disease 2019. (PubMed, Sci Rep) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid-19. (PubMed, Clin Transl Sci) - "This narrative review critically examines the pharmacological and methodological factors that contributed to these unsuccessful outcomes, paying particular attention to tests of azithromycin and hydroxychloroquine. The relative success of antivirals including molnupiravir, nirmatrelvir, and remdesivir, which were either novel or previously unapproved compounds, suggests the value of designing and developing targeted antivirals. We must coordinate global research, develop pharmacologically sound strategies, and use evidence-based decision-making to effectively prepare for future pandemics and quickly produce effective treatments."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Antagonistic Ubiquitin Switching by USP7 and RNF40 Orchestrates KDM6A Homeostasis to License Coronavirus Susceptibility. (PubMed, Adv Sci (Weinh)) - "Pharmacological inhibition of USP7 with FT671 and XL177A reduces KDM6A stability and viral receptor expression, and confers resistance to MERS-CoV, SARS-CoV, and all major SARS-CoV-2 variants of concern, including those resistant to remdesivir in primary human airway and intestinal epithelial cells. In mice, FT671 treatment was well tolerated, reduced Ceacam1 expression, and protected against MHV-A59 infection. Collectively, our findings unveil an antagonistic ubiquitin-mediated regulatory circuit that controls KDM6A stability, viral receptor levels, and coronavirus infection."

Journal • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Targeted Protein Degradation • CEACAM1 • KDM6A • USP7

Remdesivir may exacerbate ischemic acute kidney injury through molecular alterations in PGC-1α and apoptosis pathways: An in vivo study. (PubMed, PLoS One) - "These findings suggest that RDV may exacerbate AKI by hindering mitochondrial biogenesis and promoting renal cell apoptosis, without significantly affecting overall kidney function or histopathology. Clinically, these results highlight the need for caution when using RDV in patients with impaired renal function, especially during COVID-19 treatment."

Journal • Preclinical • Acute Kidney Injury • Cardiovascular • Infectious Disease • Inflammation • Nephrology • Novel Coronavirus Disease • Renal Disease • Reperfusion Injury • ATF3 • CASP3 • CDKN1A • PPARG

Use of Recombinant Human Thrombomodulin in a Pediatric Case of COVID-19-Associated Coagulopathy: A Case Report. (PubMed, J Infect Chemother) - "A multidisciplinary treatment regimen was initiated, including intravenous immunoglobulin, remdesivir, rh-TM, corticosteroids, low-dose aspirin, and budesonide inhalation. Early recognition and individualized, stage-specific therapy may contribute to favorable outcomes. However, further studies are warranted to evaluate the safety and efficacy of rh-TM in children with CAC."

Journal • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases • Septic Shock • Thrombocytopenia

Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers. (PubMed, Am J Health Syst Pharm) - "These results build on previous research highlighting the effectiveness of early treatment initiation with remdesivir in vulnerable patients hospitalized due to SARS-CoV-2 infection."

Journal • Real-world evidence • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Management of patients hospitalized for SARS-CoV-2 infection: A real-world economic evaluation from the hospital perspective. (PubMed, Am J Health Syst Pharm) - "Our evaluation provides contemporaneous evidence of benefits and costs associated with management of individuals hospitalized for SARS-CoV-2 infection. Initiation of remdesivir was associated with minimal incremental hospitalization costs for lives saved as compared to not initiating remdesivir. Hospital pharmacy leadership can utilize this real-world evidence to appropriately budget for remdesivir treatment."

HEOR • Journal • Real-world evidence • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Molecular docking and dynamic simulation of marine natural products from soft coral-derived microbes against SARS-CoV-2 main protease and spike protein. (PubMed, Sci Rep) - "Many of the test compounds [e.g., Cottoquinazoline B and D (CQB/D), Tetraorcinol A (TOA), Versicoloritide A and C (VCA/C), Fumiquinazoline K, and Pencillanthranin A) showed stronger binding affinities compared to control antiviral drugs (nelfinavir and remdesivir) and formed favorable interactions with both Mpro and the RBD of S-protein. Molecular dynamics (MD) simulation (200 ns) analysis further revealed stable binding conformations of the top docked complexes of (1) CQB with Mpro, (2) CQB with the RBD of WT S-protein, (3) TOA with the RBD of S-protein from beta variant (4) TOA with the RBD of S-protein from Omicron variant, (5) TOA with the RBD of S-protein from Delta variant, (6) TOA with the RBD of S-protein from Gamma variant, and (7) VCA with the RBD of alpha variant. However, future in vitro and in vivo studies are still required to validate efficacy of these compounds."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Real-world effectiveness of remdesivir in immunocompromised patients hospitalized due to SARS-CoV-2 Infection: Insights to inform pharmacy practice. (PubMed, Am J Health Syst Pharm) - "Early inpatient remdesivir initiation was associated with clinically meaningful and significant survival benefits in immunocompromised patients with COVID-19, with these associations persisting in the Omicron subvariant era. These findings highlight the potential importance of early antiviral treatment in this vulnerable population while underscoring the need for further prospective studies, including randomized controlled trials, to confirm causal effects and refine treatment strategies. Clinical pharmacists have a pivotal role in ensuring institutional protocols remain aligned with current evidence so that eligible high-risk patients consistently receive appropriate therapy."

Journal • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Transplantation

Lower mortality risk associated with remdesivir plus corticosteroids vs corticosteroids alone for the treatment of patients hospitalized with SARS-CoV-2 infection in the early and later Omicron periods. (PubMed, Am J Health Syst Pharm) - "Remdesivir plus CCS was associated with a significant reduction in inpatient all-cause mortality relative to CCS alone in patients hospitalized for COVID-19 across 3 years of the Omicron period, illustrating the utility of the most recent real-world evidence to help inform treatment recommendations for inpatient providers treating patients with SARS-CoV-2 infection."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Utilization of Antiviral Treatment for Hospitalized Patients With Mild-to-moderate COVID-19 at High Risk for Disease Progression. (PubMed, J Community Hosp Intern Med Perspect) - "Providers listed mild symptoms as the most common reason (74.7 %) that antiviral treatment was not started. These findings show that antiviral medications are underutilized in treating high-risk hospitalized patients with mild-to-moderate COVID-19 to prevent disease progression."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

ASTROVIRUS ENCEPHALITIS STATUS POST STEM CELL TRANSPLANT (EBMT 2026) - "Preparative regimen was TBI (1200 cGY), cyclophosphamide, thiotepa, and distal rabbit ATG without GVHD prophylaxis...Therapies included empiric cidofovir for adenovirus viremia, and therapeutic plasma exchange (TPE) for a possible immune-mediated process...mNGS of CSF subsequently identified human astrovirus VA1, establishing the diagnosis.Antiviral treatments included: administrations of high-dose IVIG, ribavirin, nitazoxanide and remdesivir... Astrovirus encephalitis is a rare but important cause of neurologic decline after HSCT, particularly in patients with T-cell dysfunction. Diagnosis often requires mNGS, as routine CSF testing may be negative. Early consideration of atypical neurotropic viruses is essential when evaluating unexplained encephalopathy in post-transplant patients due to the high morbidity and mortality."

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • CNS Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation • KMT2A

COMBINATION ANTIVIRAL TREATMENT IS EFFECTIVE IN TREATING PARAINFLUENZA 3INFECTION IN THE IMMEDIATE POST-TRANSPLANT SETTING, INCLUDING IN PATIENTS WITH IN-VIVO T-CELL DEPLETION (EBMT 2026) - " Case 1:A 9-month-old male received a Fludarabine(160mg/m2)/Treosulfan(36g/m2)/Thiotepa(10mg/kg) (FTT)-Alemtuzumab (1g/kg) conditioned 12/12 HLA-Matched Unrelated Donor Bone Marrow HSCT for high-risk Infant Acute Lymphoblastic Leukaemia...She was treated with IVIg (D+14), Ribavirin(D+14), and Remdesivir(D+15), with rapid complete resolution of symptoms, and rapid rise (i.e. decrease in viral load) in Parainfluenza Ct values on throat swabs.Case 3:A 15-year-old female with severe aplastic anaemia and fungal pneumonia was admitted for a Fludarabine(150mg/m2)/Cyclophosphamide(120mg/kg)-Alemtuzumab (0.3mg/kg) conditioned 12/12 HLA-Matched Sibling Bone Marrow HSCT...There were liver function test derangements in Case 1 (Bilirubin 46μmol/L, ALT 3x upper limit of normal (ULN), AST 5xULN) requiring dose interruption of Nitazoxanide/Favipiravir, but this was in the context of significant deterioration in clinical condition... Combination therapy with Ribavirin, Remdesivir,..."

Post-transplantation • Preclinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Otorhinolaryngology • Pneumonia • Respiratory Diseases • T Acute Lymphoblastic Leukemia • Transplantation

An Integrated NMR Approach for Evaluating Linker-Payload Conjugation with Monoclonal Antibodies. (PubMed, Bioconjug Chem) - "the properties of the bound linker-payload fragment. In this study, we chose Trastuzumab as a well-known mAb and a Remdesivir-derived fragment as a linker-payload model system to validate our approach."

Journal

Analysis of Ibuzatrelvir's Activity Against SARS-CoV-2 Circulating Variants and In Vitro Resistance Mutations. (PubMed, Antiviral Res) - "Cross-resistance testing revealed that this double substitution retained susceptibility to remdesivir and also conferred resistance to nirmatrelvir. Ibuzatrelvir and nirmatrelvir remained active against viruses containing the ensitrelvir-specific resistance Mpro substitution M49L. The sustained efficacy of ibuzatrelvir against circulating variants, combined with the low prevalence of the E166V substitution, supports its continued evaluation in phase 3 studies."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Treatment Duration of Each Anti-COVID-19 Agent Used in a Tertiary Hospital in Japan. (PubMed, Cureus) - "Four anti-COVID-19 agents, nirmatrelvir/ritonavir (Nir/r), ensitrelvir (ESV), molnupiravir (MPV), and remdesivir (RDV), have been used in Japan for adult patients, and their clinical effectiveness, especially treatment duration and reduction of viral antigen titers, was investigated. However, the treatment durations differed significantly: 4.09 days with Nir/r, 4.76 days with ESV, 4.74 days with MPV, and 5.08 days with RDV. These data suggest that the anti-viral activity of each anti-COVID-19 agent may differ in clinical use."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 in an adult with right isomerism and Fontan circulation: Successful management using risk stratification. (PubMed, Fujita Med J) - "Treatment with remdesivir and dexamethasone following Japanese treatment protocols resulted in clinical improvement and discharge without hemodynamic complications. COVID-19 pneumonia risks disrupting Fontan circulation in affected patients. This case illustrates the importance of prompt risk stratification using anatomical and physical evaluation and adherence to treatment guidelines in the management of patients with Fontan circulation and COVID-19."

Journal • Acute Respiratory Distress Syndrome • Cardiovascular • Heart Failure • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Acute Management of Measles: A Systematic Review of Therapeutic Strategies. (PubMed, Antiviral Res) - "Investigational therapeutics, including polymerase inhibitors such as ERDRP-0519, monoclonal antibodies targeting the fusion protein, and antiviral candidates such as remdesivir, offer promising future options. While vaccination remains essential, adjunctive therapies provide additional tools to reduce complications in under-vaccinated populations."

Journal • Review • Infectious Disease • Measles

A Successful Lung Transplantation in a Patient With Active Coronavirus Disease 2019: A Case Report. (PubMed, Transplant Proc) - "In carefully selected patients with limited donor availability, lung transplantation may be considered in active COVID-19 infected patient, accompanied by a tailored regimen of antiviral therapy and immunosuppression."

Journal • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • Transplant Rejection • Transplantation

MG-101, a cysteine protease inhibitor identified through high-throughput screening, exhibits in vivo efficacy and synergy with remdesivir against SARS-CoV-2. (PubMed, Biomed Pharmacother) - "Docking analysis and enzymatic assays demonstrated that MG-101 inhibits the SARS-CoV-2 3CL protease, and combination studies revealed in vitro synergistic antiviral activity with remdesivir. Together, these findings establish MG-101 as a potential therapeutic lead for COVID-19 and illustrate the value of image-based high-throughput screening for accelerating antiviral drug discovery."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Integrated viral resistance analysis in participants with COVID-19 treated with remdesivir across six phase III clinical studies (ESCMID Global 2026) - No abstract available

Clinical • P3 data • Infectious Disease • Novel Coronavirus Disease

Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations. (PubMed, Pharmacoecon Open) - "Cost effectiveness varied widely across studies due to differences in variant periods, population risk profiles, model assumptions, and healthcare systems. Future research should integrate variant-specific effectiveness, real-world vaccine responsiveness, long-term COVID-19 outcomes, and adverse events to better inform resource allocation for transplant and other high-risk populations."

HEOR • Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Transplantation

Evaluating drug interaction risks of nirmatrelvir and ritonavir combination (Paxlovid®) and remdesivir with concomitant medications in real-world clinical settings in an upper-middle-income country (ESCMID Global 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease • Novel Coronavirus Disease